Vitamin D Deficiency Clinical Trial
Official title:
Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma COPD Overlap(ACO) Patients: A Blinded Randomized Control Trial
Title:Impact of vitamin D administration on cardiac autonomic tone in Asthma Chronic
Obstructive Pulmonary Disease (COPD) Overlap patients: A blinded randomized control trial.
Background: Respiratory disease is closely associated with cardiovascular disease. Reduced
Heart Rate Variability (HRV), reflecting impaired autonomic activity have been reported in
both asthma and COPD. Vitamin D deficiency is a common feature in Asthma COPD Overlap (ACO)
patient. Relationship between vitamin D deficiency and low HRV has been reported. Vitamin D
administration has been reported to improve cardiac autonomic modulation in healthy subjects
in response to external stressor. Objective: To assess the changes in cardiac autonomic tone
after vitamin D administration for 90 days in vitamin D deficient ACO patients.
Hypothesis:Null: Vitamin D administration does not have impact on cardiac autonomic tone in
vitamin D3 deficient ACO patient.
.Method: This randomized controlled trial will be conducted by Department of Physiology,
Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka from September' 2017 to
August' 2018. For this study, a total number of 60 subjects (age > 40 years, both male and
female) will be randomly selected. 30 diagnosed vitamin D deficient Asthma COPD Overlap (ACO)
patients will form group A and another 30 diagnosed vitamin D3 deficient ACO patients with
similar age, sex, (Body Mass Index) BMI will constitute control group B. Patients of study
group B0 will take vitamin D3 with a prescribed schedule for 3 months and followed up after 3
months (group B90). On the other hand patients of group A1 will be given placebo and followed
up after 3 months (group A90). All these patients will continue their medication prescribed
by physician during these 3 months. On the basis of data recording - group B1 and group B90
will constitute pre and post vitamin D group whereas group A0 and group A90 will represent
pre and post placebo follow up at day 0 and day 90. Cardiac autonomic nerve function will be
assessed by recording ECG & Heart Rate Variability (HRV) analysis by a data acquisition
device, powerlab 8/35, AD instruments, Australia. HRV measures of all patients will be
recorded at baseline.Then after 3 months of follow up it will be recorded in both groups at
day 90. Serum 25(OH)D level will be measured of all subject at day 0 and day 90. For
statistical analysis unpaired and paired "t" test will be done by using Microsoft Office
Excel Word version 2016
Previous studies reported earlier age of onset, symptom with longer duration, more
exacerbation and devoid of adequate health care in Asthma Chronic Obstructive Pulmonary
Disease (COPD) Overlap (ACO) patients compared to asthma and Chronic Obstructive Pulmonary
Disease (COPD) alone. However their prevalence rate was reported between 15 and 55%.
Existence of asthma and COPD has been reported in between 15-20% of patient. There is no
population based data on ACO patients in Bangladesh. But one study very recently reported
11.6% of Asthma COPD Overlap (ACO) patients in this country. Thus it is of utmost importance
to perform more research on this significant disease.
Several studies investigated autonomic function in asthma and COPD patients. Both asthma and
COPD affect cardiac autonomic function. Poor asthma control is associated with lower HRV,
depressed sympathetic and enhanced parasympathetic modulation. It has reported that the risk
of cardiovascular disease in COPD is increase by 2 to 3 fold and it is the leading cause of
death in mild to moderate COPD. But to the best of our knowledge no study investigated the
cardiac autonomic function of ACO patients.
Vitamin D deficiency is a common feature in ACO patient. Previous studies demonstrated the
relationship between vitamin D deficiency and reduced HRV resulting in incidence of
cardiovascular disease. Only one study reported the effect of vitamin D administration on
HRV. They enrolled young healthy subjects and observed the effect of vitamin D on HRV in
response to physiological stressor such as angiotensin II induced stress. All these subjects
were vitamin D insufficient and their result showed improvement of sympathovagal balance
after administration of vitamin D. With this experimental observation we can expect,
administration of vitamin D in vitamin deficient ACO patients might improve cardiac autonomic
function and thereby protect them from the risk cardiovascular morbidity and mortality.
However vitamin D appears to be a simple, cost effective treatment to reduce cardiovascular
disease associated risk by improving function of autonomic nerve function in both healthy and
chronic disease population worldwide. But the volume of information regarding the effect of
vitamin D administration in ACO patients is not enough for reaching any final conclusion.
Moreover, with the best of our knowledge no study have been conducted to observe the effects
of this fat soluble vitamin on HRV in vitamin D deficient, stable patients with ACO.
Therefore, on the basis of this background the present study has been designed to evaluate
the effects of Vitamin D on heart rate variability in D deficient, stable patients with ACO.
This study will draw attention of the physicians on the cardiac autonomic status of ACO
patients and the effects of Vitamin D on it.
General Objectives:
This study will assess the impact of vitamin D therapy on cardiac autonomic tone in vitamin D
deficient ACO patients by heart rate variability analysis.
Specific Objectives:
- To measure HRV by time domain and frequency domain and nonlinear methods in vitamin D
deficient ACO patient at baseline.
- To measure all these above parameters after 3 months of vitamin D and placebo
administration.
- To Compare pre and post intervention HRV parameters in both vitamin D group and placebo
group of ACO patients.
Methods
1. Study design:
This study will be a randomized controlled trial where experiment will be done with
either vitamin D therapy or with placebo for 3 months onward.
2. Study center:
This study will be carried out in the department of Physiology of Bangabandhu Sheikh
Mujib Medical University (BSMMU), Dhaka under continuous supervision and monitoring.
3. Period of study:
This study will commence from September, 2017 and expected to end by August, 2018.
4. Ethical Clearance:
The protocol of this study involving the human subjects will be submitted to
Institutional Review Board (IRB) of Bangabandhu Sheikh Mujib Medical University (BSMMU)
for ethical and other technical approval before commencing the actual study.this project
is a part of an ongoing research which was approved by Institutional Review Board (IRB)
of Bangabandhu Sheikh Mujib Medical University (BSMMU).
5. Sampling:
Sample size:
Total 60 subjects will be recruited in this study, which is designed for randomized
controlled trial on the basis of outcome measures (effect size) i.e. estimation of mean
differences between pre & post intervention mean of the study which has already been
published in a cross sectional study that assess the association of vitamin D deficiency with
cardiac autonomic activity. Sample size based on effect size .
Sampling Technique:
Simple random sampling will be adopted to select the patients. According to the selection
criteria total 60 subjects of both male and female with specific age range suitable for the
aim and objective of the study will be enrolled. These diagnosed ACO patients (diagnosed by
applying the "tick box" approach recommended by the joint committee of GOLD & GINA from Out
Patient Department (OPD) of NIDCH) will be selected by clinicians in OPD of National
Institute of the Disease of Chest and Hospital (NIDCH).
Grouping of the subjects:
After a careful brief interview, selection and enrollment of the subjects for this study will
be done. All the subjects will be divided into following groups according to the objectives
of the study
Baseline group:
This group will include 60 vitamin D deficient ACO patients.
Group A:
25 diagnosed vitamin D deficient ACO patients will be included in this group and they will be
given vitamin D. This group will be further divided into the following group.
Group A0: Vitamin D deficient ACO patients with placebo at day 0. Group A90: Vitamin D
deficient ACO patients with placebo at day 90
Group B:
25 diagnosed vitamin D deficient ACO patients will be included in this group and they will be
given placebo. This group will be further divided into the following group.
Group B0: Vitamin D deficient ACO patients with vitamin D at day 0. Group B90: Vitamin D
deficient ACO patients with vitamin D at day 90.
All the patients will be similar by age, sex and BMI.
8. Study intervention:
The intervention will be given by oral administration of vitamin D3 capsule each of which
contain 40000 International Unit (IU) of vitamin D. The capsule will be manufactured and
supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo will also be manufactured
and supplied by the same pharmaceutical company and will be similar in size shape &
appearance to vitamin D capsule but it will contain sucrose powder. All patients will be
advised to take 2 capsule after breakfast on a fixed day of the week for 3 consecutive
months.
At the time of enrollment all patients will be randomized to one of the two interventions
(placebo or vitamin D) immediately. The intervention will be double blind randomized and
cross over design so that each patient will act as his/her control. Each participant of the
placebo group & vitamin D3 group will be studied before & after intervention and comparison
will be done between these two groups. In addition comparison will be done post intervention
data of placebo & vitamin D group.
9. Study procedure:
On the first day of enrollment the researcher will introduce herself to the patient and ask
for permission to talk to them. Then she will cordially explain about the objectives,
purpose, and procedure of the study on the day of enrollment. The benefit as well as risk (if
any) of the study should be carefully mentioned. Special emphasis will be given on explaining
how he/she will be benefited from this study. The patient will be motivated for voluntary
participation and will be allowed to withdraw him or herself from the study even after
participation, whenever the patient feels uneasy. If he or she agrees to be a part of the
study, an informed written consent will be taken in a prescribed form. Detailed family
history, medical history and thorough physical examination of each patient will be done and
all the information will be recorded in a standard data sheet. Then all the patients will be
requested to attend the Department of Physiology at 8:30 am on the day of biochemical
examination On the examination day, 5 ml of venous blood will be collected and taken to the
biochemistry laboratory as soon as possible for the estimation of serum 25(OH)D. BMI will
also be calculated by recording height weight. After getting the biochemical report, the
final selection will be done, according to the inclusion and exclusion criteria..
Randomization and blinding: As it is not possible to exclude ACO patient with hypertension
and/or diabetes , we will apply stratified randomization technique according to these two
confounding factors. Four strata will be formed, as hypertension, diabetes, diabetes with
hypertension and without hypertension and diabetes. Whenever a patient will be selected for
enrollment, he will be given an Identification Number (ID) and assigned to one of the four
strata according to his characteristics.
The randomization and blinding design was developed by a faculty of the Department of
Physiology who is not included in the study team. The ID number and stratification will
informed to the faculty. She (the faculty) will then then randomly allocate the patient in
either group A (placebo) or group B (vitamin D) considering his strata so that both the group
had equal number of patients from each strata. The faculty will then note down the patient ID
in the allotted group and supplied principal investigator (PI) the drug (placebo or vitamin
D) according to the allotted group.
At the end of the study, the faculty will provide the list of the patient's ID with allotted
group to the PI
Data collection: All the selected patients will be then requested to come to the Department
again on the next day for the HRV test with proper preparation.
Preparation for HRV test: Preparation for the test will be explained to them. For HRV
examination, the subject will have to take their meal by 9:00 pm and need to have a sound
sleep in the previous night. From previous night up to the time of examination, they will be
requested not to undergo any physical or mental stress and also avoid taking any sedatives or
any other drugs that affect central nervous system (Task force, 1996).The patients will be
requested to take light breakfast in the morning without tea or coffee. After that, the
selected subjects will be kept in complete bed rest in supine position for 10-15 minutes in
the cool and calm laboratory environment to adjust with the lab conditions. During this
period, the subject will be advised not to talk, eat or drink and also not to perform
physical or mental activity even sleep .
Laboratory conditions and recording of HRV: The recording of HRV measures will be done by 8
active channels, power lab 8/35 (AD instrument, Australia), in the Autonomic Nerve Function
Laboratory of Department of Physiology, BSMMU. The temperature of the laboratory will be
maintained at 25°C-28°C and lights will be kept dim. It will also be maintained noise free.
Door of the lab will be closed and no one will be allowed to enter the room during the test
except the investigator and the subject.
Once the HRV recording will be completed, the patients will be provided the drug (containing
placebo or vitamin D3 ) and will be asked to take 2 capsule per week for consecutive 90 days.
The schedule of the therapy will be explained meticulously in detail to the patients. He/she
will also be informed about the possible side effect of the drug (e.g. diarrhea). If the
subject is able to understand everything explained to him, then he/she will be advised to
continue the drug therapy for the consecutive 90 days. If the subject finds it difficult to
understand the intervention or if any side effect of the drug appears, he/she will be asked
to come to the department or to contact via telephone. During this period, the subjects will
be regularly monitored and encouraged to be the part of this study by maintaining regular
communication through telephonic calls several times a week. A good rapport will be built up
to take time to time follow-up over telephone and visiting patient's place. In addition,
scheduled appointment, hot-line and follow up will be maintained properly. If the subject
finds it difficult to understand the intervention or if any side effect of the drug appears,
he/she will be asked to come to the department or to contact via telephone. All the selected
ACO patients will be allowed to continue standard therapeutic treatment as prescribed by the
physician for these three months. Along with this, all the subjects of both the groups will
be advised to continue a diet according to their own choice. Subsequently, all subjects will
be requested to attend the Department of Physiology, BSMMU again on the 90th day for
assessment of all the above-mentioned study variables. Any subject who fails to follow the
study procedure exactly during the study period will be dropped and a new one will be
included to fulfill the desired total sample size. At the end of the study i.e. after 90 day
vitamin D3 will be given to all the patients of placebo group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Completed |
NCT01688102 -
The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile
|
N/A | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 |